Johnson & Johnson Lifts FY26 View, Despite Nearly Flat Q2 Profit; Stock Down

Drug major Johnson & Johnson, while reporting slightly lower second-quarter profit despite sales growth, on Wednesday raised again its earnings and sales forecast for fiscal 2026. The company also announced a quarterly dividend. In pre-market activity, the shares were losing around 1.9 percent.

You are being sent to the original publisher. FX Radar keeps this reference for market context and source discovery.